All In Biotech

Drug Trial Radar · NCT03619850

A Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

A Phase 3, Randomized, Open-Label, Multicenter Study to Evaluate the Safety (Compared to Iron Sucrose), Efficacy and Pharmacokinetics of Ferumoxytol for the Treatment of Iron Deficiency Anemia (IDA) in Pediatric Subjects With Chronic Kidney Disease (CKD)

Last checked: Nov 20, 2026Latest source record: Apr 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 129 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

129

Planned (sponsor's estimate)

Start

Aug 13, 2018

Primary completion

Aug 31, 2026

Study completion Aug 31, 2026

Sponsor

Lead sponsor
AMAG Pharmaceuticals, Inc.Industry
Sponsor type
Industry
First posted
Aug 8, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 2 years, up to 17 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Primary Objectives: To evaluate the safety (compared to iron sucrose) and efficacy of ferumoxytol in pediatric CKD subjects with iron deficiency anemia (IDA) or who are at risk of development of IDA Secondary Objective: To determine the single-dose pharmacokinetics (PK) and pharmacodynamics (PD) profile of ferumoxytol in pediatric subjects.

Conditions

  • Chronic Kidney Disease; Iron Deficiency Anemia

Interventions

  • FerumoxytolDrug

    Each 20 mL single-use vial contains 17 mL of ferumoxytol that consists of iron at a concentration of 30 mg Fe/mL, coated with polyglucose sorbitol carboxymethylether and formulated with mannitol, at a concentration of 44 mg/mL, in a black to reddish brown sterile, aqueous, colloidal, isotonic solution.

  • Iron sucroseDrug

    Each mL contains 20 mg of elemental iron as iron sucrose in water for injection. The 5 mL single-use vial contains 100 mg of iron per 5 mL. The drug product contains approximately 30% sucrose (300 mg/mL).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Hemoglobin change of at least 0.5 g/dL from Baseline to Week 5Time frame: 35 days

Locations

21 sites in 5 countries. Site status is shown where the registry gives one.

  • Memorial Healthcare System

    Hollywood, Florida · Not yet recruiting

  • Wayne State University

    Detroit, Michigan · Active not recruiting

  • Children's Mercy Hospital

    Kansas City, Missouri · Recruiting

  • The Feinstein Institute Medical Research Organization of Northwell Health, Inc.

    Lake Success, New York · Not yet recruiting

  • Icahn School of Medicine at Mount Sinai (ISMMS) - The Mount Sinai Hospital (MSH)

    New York, New York · Active not recruiting

  • Montefiore Medical Center (MMC) - The Children's Hospital at Montefiore (CHAM)

    The Bronx, New York · Recruiting

  • Akron Nephrology Associates, Inc.

    Akron, Ohio · Recruiting

  • West Virginia University

    Morgantown, West Virginia · Recruiting

  • Semmelweis Egyetem - Altalanos Orvostudomanyi Kar (SE AOK) - I. sz. Gyermekgyogyaszati Klinika

    Budapest, Hungary · Recruiting

  • University Of Szeged

    Szeged, Hungary · Recruiting

  • Hospital of Lithuanian University of Health Sciences Kauno klinikos

    Kaunas, Lithuania · Not yet recruiting

  • Klaipeda Children's Hospital

    Klaipėda, Lithuania · Active not recruiting

  • Vsl Vilniaus Universiteto Vaiku Ligonine (VUVL) (Vilnius University Children's Hospital)

    Vilnius, Lithuania · Not yet recruiting

  • Instituto Mexicano De Trasplantes S.C

    Cuernavaca, Mexico · Recruiting

  • JM Research, SC

    Cuernavaca, Mexico · Active not recruiting

  • Hospital Civil de Guadalajara Fray Antonio Alcalde

    Guadalajara, Mexico · Recruiting

  • Instituto Nacional de Pediatria (INP) (National Institute of Pediatrics)

    Mexico City, Mexico · Recruiting

  • Uniwersytecki Szpital Kliniczny Im. Zamenhofa w Bialystoku

    Bialystok, Poland · Not yet recruiting

  • Specjalistyczne Gabinety Sp. z o.o

    Krakow, Poland · Active not recruiting

  • University Children Hospital

    Krakow, Poland · Not yet recruiting

  • Polish Mother's Memorial Hospital Research Institute

    Lodz, Poland · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.